(PDF) Early Changes in Retinal Thickness When Using

Early Changes in Retinal Thickness When Using Intravitreal Ranibizumab for Age‐related Macular Degeneration

Acta Ophthalmologica - United States

doi 10.1111/aos.13972_470

Full Text

Abstract

Available in full text

Categories

Date

December 1, 2018

Authors

Unknown

Publisher

Wiley

Related search

Peripapillary Choroidal Thickness After Intravitreal Ranibizumab Injections in Eyes With Neovascular Age-Related Macular Degeneration

BMC Ophthalmology

English

Effect of ARMS2 Gene Polymorphism on Intravitreal Ranibizumab Treatment for Neovascular Age-Related Macular Degeneration

Genetics and Molecular Research

Molecular Biology

English

Ranibizumab Versus Verteporfin for Neovascular Age-Related Macular Degeneration

New England Journal of Medicine

English

Macular Functional Changes in Patients With Neovascular Age-Related Macular Degeneration Receiving Ranibizumab Therapy (Lucentis)

English

Choroidal Blood Flow After the First Intravitreal Ranibizumab Injection in Neovascular Age-Related Macular Degeneration Patients

Acta Ophthalmologica

English

Intravitreal Injection of Ranibizumab Using A pro Re Nata Regimen for Age-Related Macular Degeneration and Vision-Related Quality of Life

Clinical Ophthalmology

English

Focal Macular Electroretinograms After Intravitreal Injections of Bevacizumab for Age-Related Macular Degeneration

Investigative Ophthalmology and Visual Science

Molecular Neuroscience

Sensory Systems

English

Patterns of Early and Delayed Visual Response to Ranibizumab Treatment for Neovascular Age-Related Macular Degeneration

JAMA Ophthalmology

English

Effects of Intravitreal Ranibizumab on the Untreated Eye and Systemic Gene Expression Profile in Age-Related Macular Degeneration [Corrigendum]

Clinical Interventions in Aging

English